Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  For the Patient  |  Careers at Hemispherx  


Research and Development
Drug Candidates
Patent Portfolio
Clinical Trial Information
Abstracts and Scientific Information
Professional Services
Educational Resources

Product Candidates Under Development

HEMISPHERx BIOPHARMA, Inc. has developed over nearly three decades a vast body of knowledge relating to a potentially new class of pharmaceutical products (nucleic acid compounds) that are designed to activate otherwise dormant cellular defenses against viruses and tumors. We pursue commercialization of our products and have a strong and broad-based patent base.
 
 
 

Indication

Product Candidate

Status

CFS/ME

Ampligen®

Phase 3  Completed (USA)

HIV

Ampligen®

Phase 2b Ongoing (USA)

HIV

Ampligen®

Phase 3 Preparation (China)
Avian Flu Ampligen® Preclinical Studies (USA, Japan and Canada)

Hepatitis C

Alferon N Injection®

Phase 3 Preparation (China)
Multiple Sclerosis Alferon N Injection® Phase 2 Preparation (USA)

West Nile Virus

Alferon N Injection®

Phase 2/3 Preparation - Investigator Sponsored (USA)
Antiviral Indications Alferon LDO® Phase I/II Ongoing (USA & Hong Kong)

HIV

Alferon LDO®

Phase 2 Preparation (Africa)
Avian Flu Alferon N Injection® / Alferon LDO® Preclinical Studies (USA and Canada)

Various

Oragens™

Preclinical Studies

 

 
 
Information contained on the Hemispherx website other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed on the Hemispherx website and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgement as of the date of this website. The Company disclaims, however, any intent or obligation to update these forward-looking statements.